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ABSTRACT 
Myostatin is a negative regulator of muscle growth. Loss of myostatin function 
results in a dramatic phenotype in several species including cattle, mice, dogs and 
humans. Myostatin mutants exhibit wide-spread hypermuscularity and decreased fat 
accumulation. Though the phenotype of myostatin mutant animals is very striking, the 
question remains whether the loss of myostatin function fundamentally changes growth 
potential, metabolism, or inherent regulation in tissues, or if it is simply an effect 
independent of other factors. To that end, we sought to increase muscle growth even 
further in myostatin null mice through the use of the β-adrenergic agonist clenbuterol. 
The effects of clenbuterol treatment and the loss of myostatin function are quite similar 
and, in this study, were completely additive. Clenbuterol treatment increased muscle 
weights and protein accretion and reduced fat accumulation in both wild type and 
myostatin null mice. There was a significant interaction of genotype and clenbuterol 
treatment for gastrocnemius muscle weight, but the magnitude of the differences in 
weight gain between myostatin null and wild type was very small. We also aimed to alter 
fat accumulation and metabolism in myostatin null mice by feeding diets high in fat. 
Other research indicated that myostatin null mice were resistant to fat accumulation 
induced by high-fat feeding. In our study, fat accumulation was increased in both wild 
type and myostatin null mice fed high-fat diets, but the magnitude of the increase in 
myostatin null mice was less than that of wild type mice. This suggests that myostatin 
null mice are partially resistant to high-fat diet-induced obesity. Markers of metabolic 
syndrome often induced by high-fat feeding in mice were also improved in myostatin null 
compared with wild type mice. Liver fat content, serum triglycerides and serum leptin 
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levels were lower in high-fat fed myostatin null mice than similarly fed wild type mice. 
Glucose tolerance, however, was altered in both genotypes by high-fat feeding and did 
not show an improvement in myostatin null mice. Given the partial resistance to high-fat 
induced fat accumulation, we investigated expression of adaptive thermogenic genes and 
found that some genes were upregulated specifically in high-fat fed myostatin null mice. 
These changes, however, likely do no fully account for the resistance to fat gain in 
myostatin null mice. Overall, we conclude from these two studies that, while the loss of 
myostatin function does have a dramatic effect in increasing muscle growth and reducing 
fat deposition, it does not represent maximal muscle or minimal fat accumulation. Muscle 
and fat tissues do respond to both beta-adrenergic agonists and to increased dietary fat 
and calories.  
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CHAPTER 1 
REVIEW OF LITERATURE 
Introduction 
 In the approximately 10 years since the identification of myostatin, a growth 
factor involved in inhibiting muscle growth, much has been made about the impressive 
increase in muscle mass resulting from mutations or inhibition of this protein. Several 
people have speculated whether myostatin inhibition may provide possible treatments for 
muscular dystrophy, sarcopenia or even lead to enhanced athletic performance. Similarly, 
the apparent leanness of these animals has also led to speculation regarding the use of 
myostatin inhibitors for the treatment of obesity and metabolic syndrome. The goal of 
experiments comprising this thesis was to determine if muscle growth due to deletion of 
the myostatin gene would render muscle and fat tissue unresponsive to further alterations. 
Clenbuterol treatment was used as an additional supplement to increase muscle growth, 
and high-fat diet-induced obesity was employed as a means of increasing fat 
accumulation.  
 
Myostatin 
Discovery and Characteristics of Myostatin-mutant Animals 
 Myostatin, originally termed growth and differentiation factor (GDF)-8, was 
identified in 1997 by McPherron, Lawler and Lee (McPherron et al., 1997) due to its 
homology with other members of the transforming growth factor (TGF)-β superfamily. 
To determine its’ biological function, this group disrupted GDF-8 in embryonic stem 
cells of mice, preventing the protein from being cleaved for activation. The resulting 
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mice were hypermuscular with individual muscles weighing double that of wild type 
mice. For several years prior to this discovery, double-muscled cattle had been noted for 
their hypermuscularity and the gene involved in this phenomenon had been mapped to 
chromosome 2 and termed the mh locus for its’ involvement in muscle hypertrophy 
(Charlier et al., 1995; Dunner et al., 1997). Soon after the discovery of myostatin, it was 
determined that the mh locus was indeed the myostatin gene (Grobet et al., 1997; Grobet 
et al., 1998; Kambadur et al., 1997; McPherron and Lee, 1997). The unifying features of 
myostatin mutants, which have now been identified or created in several species, include 
pronounced increases in muscle mass due to both hyperplasia and hypertrophy 
accompanied by decreased fat accumulation.  
Several different mouse models involving myostatin have been identified or 
generated including the original myostatin null mouse (McPherron et al., 1997). When 
compared to wild type littermates, myostatin null mice are 30% heavier. This additional 
body weight is the result of widespread increases in muscle mass. Individual muscles of 
myostatin null mice weigh two to three times that of wild type mice. The increase in body 
weight observed at 3 months of age is attributed primarily to an increase in muscle 
weight because the myostatin null, as a proportion of body weight, has less adipose tissue 
than the wild type. At its widest point, the tibalis anterior (TA) muscle of the myostatin 
null contains 86% more muscle fibers than wild type controls. Per gram of tissue, the TA 
muscle contains 50% more DNA. Additionally, the mean cross sectional area of 
individual fibers is increased 7% and 22% in the TA and gastrocnemius muscles, 
respectively. Furthermore, the protein:DNA ratio is increased in the myostatin null 
3 
 
animal when compared to the wild type. These changes are observed in both male and 
female myostatin null mice (McPherron et al., 1997).  
However, other mouse models involving myostatin do exist. A hypermuscular 
line of mice developed from long-term selection for growth possess a mutation in the 
propeptide region of myostatin which may impact dimerization of the protein (Szabo et 
al., 1998). Transgenic expression of myostatin inhibitors (Lee and McPherron, 1999) or 
overexpression of the propeptide of myostatin (Yang et al., 2001) result in 
hypermuscularity, though increased muscle mass in the propeptide overexpressing mice 
results from increased hypertrophy and not altered hyperplasia. Despite the presence of 
these other models, the original myostatin null mouse continues to be the most-
commonly used model for research into myostatin function.  
 First described in 1807 (Culley, 1807), double-muscling has been reported in 
several breeds of cattle including Belgian Blue, Blonde d'Aquitaine, Charolais, 
Gasconne, Limousin, Maine-Anjou, Parthenaise, Asturiana, Rubia Gallega, and 
Piedmontese. The double-muscling phenomenon in all these breeds except Limousin and   
Blonde d'Aquitaine results from loss-of-function mutations in myostatin (Grobet et al., 
1998). Similar to other myostatin mutants, double-muscled cattle have increased muscle 
mass and reduced fat and bone mass, thought to reflect an alteration in nutrient 
partitioning (Shahin and Berg, 1985). Double-muscled cattle have leaner carcasses than 
normal cattle and are more efficient at converting food to body tissue (Arthur, 1995). 
These animals have an increased amount of saleable meat product and therefore, have the 
potential to increase profits. However, the use of double-muscled cattle is somewhat 
difficult in a production system due to reduced fertility and the need for calving 
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assistance due to increased dystocia. Meat from double-muscled cattle, reflective of 
leaness throughout the body, is often lacking in intramuscular fat, or marbling. However, 
it has been reported that double-muscled cattle have less connective tissue within the 
muscle and therefore, are more tender (Hanset, 1991).  
The bully whippet is another example of a naturally occurring myostatin 
mutation. Whippets normally resemble greyhounds, but the bully whippet, possessing a 
two-base-pair deletion in the third exon of myostatin, exhibits a wide-spread increase in 
muscling. Like greyhounds, whippets are often used in racing; dogs heterozygous, but not 
homozygous, for the mutation show increased race performance being significantly faster 
than normal whippets (Mosher et al., 2007). In contrast to other myostatin mutants, Texel 
sheep do not have a mutation in the coding region of myostatin. Texel sheep, renowned 
for their meatiness, posses a mutation in the 3’ untranslated region of the myostatin gene 
which affects the binding of two microRNAs which are strongly expressed in muscle. 
This results in downregulation of myostatin translation and reduced circulating myostatin 
by two-thirds contributing to their increased muscle hypertrophy (Clop et al., 2006). 
Finally, there is one human with a confirmed mutation of myostatin; this German boy 
exhibited increased muscle mass and strength from birth (Schuelke et al., 2004).  
The myostatin gene has been mapped to chromosome 2 in humans and in other 
species including cattle, mice and sheep (Charlier et al., 1995; Clop et al., 2006; Szabo et 
al., 1998). The human gene contains 3 exons which encode for 125, 124 and 126 amino 
acids each (Gonzalez-Cadavid et al., 1998). The promoter region of the myostatin gene 
has multiple response elements for glucocorticoids, androgens, monocyte enhancing 
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factor, peroxisome proliferator-activated receptor gamma, and nuclear factor κ-β (Ma et 
al., 2001).  
Myostatin mRNA is primarily expressed in muscle and is detected as early as 9.5d 
post-coitus in mice (McPherron et al., 1997) and 21d post-conception in swine (Ji et al., 
1998). Myostatin, however, has also been documented in the heart (Sharma et al., 1999), 
the lactating mammary gland of swine (Ji et al., 1998), brain and ovarian tissue in fish 
(Roberts and Goetz, 2001; Rodgers et al., 2001), and at low levels in adipose tissue in 
mice (Allen et al., 2008; McPherron et al., 1997). Expression is influenced by several 
factors including strength training (Roth et al., 2003), disuse (Reardon et al., 2001) 
glucocorticoid treatment (Ma et al., 2003), obesity (Allen et al., 2008), and the 
administration of other myogenic factors such as MyoD (Spiller et al., 2002).  
Myostatin is a 376 amino acid peptide that is proteolytically processed into a 15 
kDa active protein. It contains all the hallmarks of growth factors belonging to the TGF-β 
superfamily and includes a proteolytic processing site, a signal sequence for secretion, 
and an active carboxy-terminal site with a highly conserved series of cysteine knots 
(McPherron et al., 1997). The carboxy-terminal end possesses 100% homology across 
mouse, rat, human, swine, chicken and turkey forms of the growth factor, suggesting that 
the function of myostatin is well-conserved (McPherron and Lee, 1997). Post-
translational cleavage frees the active protein from the propeptide, though the two parts 
remain associated and the propeptide acts as an endogenous inhibitor of myostatin 
activity (Hill et al., 2002). Transgenic overexpression of the myostatin propeptide in mice 
leads to a phenotype similar to that of myostatin null mice (Jinzeng Yang, 2006). 
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The majority of circulating myostatin is associated with its propeptide to form a 
latent complex unable to bind to receptors (Hill et al., 2003). Myostatin is also inhibited 
by follistatin, follistatin related gene proteins (FRG-P) and GDF-associated serum protein 
(GASP-1) (Hill et al., 2002; Hill et al., 2003; Lee and McPherron, 2001). The mechanism 
of myostatin activation in vivo is unknown. Once free, myostatin binds to activin type II 
receptors (ActIIB) leading to the activation of type I receptors and the Smad proteins 
(Lee and McPherron, 2001).   
Impact on Muscle Development, Growth and Atrophy 
In C2C12 cells, a well-known mouse myoblast cell line (Del Aguila et al., 1999; 
Milasincic et al., 1996; Semsarian et al., 1999), myostatin treatment decreased 
proliferation as well as DNA and protein synthesis (Rios et al., 2002; Taylor et al., 2001; 
Thomas et al., 2000). Furthermore, myostatin treatment increased the number of 
myoblasts observed in the G1 and G2 phase of the cell cycle and decreased the number of 
myoblasts in the S phase (Joulia et al., 2003). These data indicate that myostatin may 
modulate muscle development by targeting the cell cycle.   
Cell cycle progression from the G1 to the S phase requires phosphorylation of the 
retinoblastoma susceptibility gene product (Rb) by cyclin-cyclin dependent kinase (Cdk) 
complexes. Hypophosphorylated Rb binds to transcription factors important in S phase 
gene activation such as E2F-DPI and prevents progression into the S phase. 
Phosphorylation of Rb by G1 Cdks releases these factors allowing passage through the 
G1/S checkpoint (La Thangue, 1996).  
In response to myostatin signaling, there is an increase in the expression of the 
cyclin kinase inhibitor p21 and a decrease in both the level of Cdk 2 and its activity 
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resulting in accumulation of hypophosphorylated retinoblastoma. This leads to an arrest 
of myoblasts in the G1 phase of the cell cycle (Thomas et al., 2000). In the absence of 
myostatin, high levels of p21 are not present and Cdk2 remains active. Thus, the Rb 
protein becomes hyperphosphorylated and the cells enter the S phase of the cell cycle. In 
the case of animals with loss-of-function mutations, the absence of myostatin signaling 
ultimately leads to increased proliferation of myoblasts during development and an 
increased number of mature muscle fibers. Normal myostatin signaling results in cell 
cycle arrest of myoblasts thereby negatively influencing muscle development.  
 Myostatin can also inhibit myoblast differentiation. Myostatin treatment of C2C12 
cells decreased MyoD and myogenin mRNA and protein levels and downregulated the 
activity of their downstream target, creatine kinase (Joulia et al., 2003; Rios et al., 2002). 
Langley and co-workers (2002) observed increased Smad3 expression and association 
with MyoD in response to myostatin treatment. This resulted in a decrease in myoblast 
differentiation that could not be rescued with MyoD treatment, suggesting that the effect 
of myostatin may be mediated through modulation of muscle regulatory factor activity. 
This theory is supported by the finding that double-muscled bovine fetuses have higher 
levels of MyoD than wild type fetuses (Oldham et al., 2001). However, Spiller and others 
(2002) showed that MyoD induced myostatin expression suggesting myostatin and MyoD 
may reciprocally regulate the others’ expression. Furthermore, though both myostatin and 
MyoD expression peak during the G1 phase of the cell cycle, myostatin was expressed at 
high levels during the G1/S-phase and G0 phases. This suggests that myostatin expression 
is controlled independently of MyoD in those phases.  
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In addition to prenatally regulating myoblast proliferation and differentiation, 
myostatin may also regulate the postnatal growth of muscle. Specific postnatal inhibition 
of myostatin leads to muscle hypertrophy (Grobet et al., 2003; Whittemore et al., 2003).  
In contrast, systemic or muscle-derived overexpression of myostatin leads to a decrease 
in muscle mass (Reisz-Porszasz et al., 2003; Zimmers et al., 2002). Postnatally, muscle 
growth is the result of satellite cell proliferation, differentiation and fusion with existing 
muscle fibers to maintain a relatively constant DNA:protein ratio (Snow, 1990). 
Myostatin expression has been detected in proliferating satellite cells in chicken and in 
culture (Kocamis et al., 2001). Additionally, the number of satellite cells per unit length 
and the number of active satellite cells was higher in myostatin null mice when compared 
to wild type. Myostatin increases p21 levels in satellite cells similar to proliferating 
myoblasts and, therefore, may hold satellite cells in a quiescent state. Thus, when 
myostatin is not present, increased satellite cell activation leads to hypertrophy 
(McCroskery et al., 2003).  
 Increased myostatin expression has been observed in several models of muscle 
atrophy (Dasarathy et al., 2004; Gonzalez-Cadavid et al., 1998; Ma et al., 2003; Reardon 
et al., 2001; Yarasheski et al., 2002). Furthermore, muscle atrophy caused by 
glucocorticoids was prevented by when the myostatin gene was deleted (Gilson et al., 
2007). Some have suggested that myostatin upregulation reduced satellite cell activity 
(Dasarathy et al., 2004; McCroskery et al., 2003). However, overexpression of myostatin 
reduced muscle mass (Reisz-Porszasz et al., 2003) and led to down-regulation of 
Akt/mTOR signaling (Amirouche et al., 2009). This suggests that the role of myostatin in 
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muscle atrophy may be due to alterations in protein synthesis in addition to muscle 
regeneration through satellite cell activity.  
 
Involvement in Adipose Tissue Regulation 
In addition to regulating muscle development and growth, it has been suggested 
that myostatin, or the lack thereof, alters adipose development or fat accumulation. As 
previously discussed, one unifying feature of myostatin mutant animals is reduced body 
fat accumulation. Myostatin null mice, unlike wild type mice, do not continue to gain 
weight after 6 months of age. Adipose tissue pad weight, adipocyte number and size are 
all reduced in myostatin null mice compared with age-matched wild type mice 
(McPherron and Lee, 2002). Serum leptin and triglyceride levels are also reduced in 
myostatin null mice (Guo et al., 2009). Decreased fat accumulation in myostatin null 
mice does not correspond with reduced feed intake, differences in body temperature 
regulation, or uncoupling protein (UCP) expression (McPherron and Lee, 2002). 
However PPARγ and C/EBPα are reduced in myostatin null animals at 12 weeks of age 
suggesting not only decreased lipid filling of adipocytes, but also decreased adipogenesis 
(Lin et al., 2002).  
Myostatin mutant animals are also resistant to fat gain under conditions which 
normally produce obesity. When the myostatin null mutation was interseminated with the 
agouti obese (Ay/a) and leptin obese (ob/ob), mutations, researchers observed reduced 
obesity and improved glucose metabolism (McPherron and Lee, 2002). Furthermore, it 
has been suggested that myostatin null and mice overexpressing the myostatin propeptide 
are resistant to high-fat diet induced obesity (Hamrick et al., 2006; Jinzeng Yang, 2006; 
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Zhao et al., 2005). This resistance to fat accumulation, however, is not always observed. 
Incorporating myostatin null alleles into mice deficient for the leptin receptor (db/db) did 
not reduce fat accumulation in 9 week old mice (Dilger, 2002). Furthermore, when fed a 
high-energy diet for several months, a double-muscled steer accumulated fat similar to a 
normal steer (Novakofski and Kauffman, 1981).  
In vitro, myostatin promotes (Artaza et al., 2005; Feldman et al., 2006) or inhibits 
(Kim et al., 2001; Zimmers et al., 2002) adipogenesis depending on the cell type used, 
suggesting myostatin may function differently during determination and differentiation. 
Direct injection of myostatin has produced conflicting results (Stolz et al., 2008; 
Zimmers et al., 2002) with some researches noting whole body cachexia including both 
muscle atrophy and fat depletion, while others note no change in body composition. 
These conflicting results may be dose-related as cachexia was induced by a super-
physiological dose.  
Though predominantly expressed in muscle tissue, myostatin is detectable in fat 
tissue as well, and is thought to be produced by adipocytes themselves and not simply by 
stromal cells associated with fat (Allen et al., 2008; McPherron et al., 1997). Myostatin is 
also upregulated in adipocytes in response to obesity while it is unchanged or slightly 
downregulated in muscle cells under the same conditions (Allen et al., 2008). Mice 
overexpressing myostatin specifically in adipocytes have normal body fat mass despite 
having smaller adipocytes, but have increased energy expenditure and are resistant to 
diet-induced obesity (Feldman et al., 2006). Mice with adipose-specific knock-out of 
myostatin did not have altered body composition or fat cell size, but were also not 
resistant to diet-induced obesity (Guo et al., 2009). These findings suggest that myostatin 
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production by adipocytes may be one mechanism by which fat attempts to limit its’ own 
growth in obesigenic conditions.    
If myostatin does indeed limit adipocyte cell growth, then it is contradictory that 
myostatin mutant animals, with little or no functional myostatin, accumulate less fat. 
Thus, the mechanism of resistance to fat accumulation in myostatin mutant animals may 
be an indirect effect of myostatin on whole-body metabolism as opposed to a direct effect 
of myostatin on adipocytes. This paradigm would be similar to other mutations which 
increased muscle hypertrophy, and therefore, resulted in less fat mass and resistance to 
diet-induced obesity (Izumiya et al., 2008; Lai et al., 2004; Musarò et al., 2001; Sutrave 
et al., 1990;). While the direct role of myostatin in altering body metabolism cannot be 
excluded, it seems plausible that changes in fat accumulation in myostatin mutant 
animals is secondary to altered muscle mass.  
 
Clenbuterol 
Generalized β-adrenergic agonist activity 
 Synthetic β-adrenergic receptor agonists (βAA), such as clenbuterol, bind to β-
adrenergic receptors (β-AR) and elicit responses similar to endogenous βAA, epinephrine 
and norepinephrine. Upon binding, the agonist-receptor complex activates Gs proteins 
which activate adenylate cyclase producing cyclic adenosine monophosphate (cAMP). 
Levels of cAMP orchestrate many intracellular events. For example, cAMP binds the 
regulatory subunit of protein kinase A, allowing the catalytic subunit to phosphorylate 
other proteins. Some of these proteins are transcription factors, such as cAMP response 
element (CREB) which binds to and increases the transcription of several genes. Other 
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proteins phosphorylated by protein kinase A are enzymes; some enzymes, like hormone-
sensitive lipase, are activated by phosphorylation while others like acetyl co-A 
carboxylase are inhibited by phosphorylation (Mersmann, 1998). Thus, binding of βAA 
to its’ receptor has both enzymatic effects and influences gene transcription.  
 There are three subtypes of β-AR labeled β1-AR, β2-AR, and β3-AR with most 
tissues containing multiple β-AR subtypes (Minneman et al., 1979). Subtype distribution 
differs both between and within tissues, and also between species. In humans, heart is the 
prototypic tissue that responds to β1-AR agonists, lung for β2-AR and fat for β3-AR. 
However, bovine adipocytes are thought to have more β2-AR (Houseknecht et al., 1995; 
Sillence and Matthews, 1994) while swine adipocytes have β1-AR as their primary 
transcript (McNeel and Mersmann, 1999). These subtype expression differences in 
adipocytes may also relate to animal age as β3-AR expression is enriched in brown 
adipose tissue of which adult swine and cattle have little (Strosberg, 1997).  
 Several agonists have been used in human medicine and in livestock production to 
activate β-AR signaling. While it is convenient to imply that one compound is more 
selective for one type of β-AR than another, the literature does not always support such 
sweeping conclusions. Moreover, findings are often confounded by the use racemic 
mixtures of βAA compounds and differences in receptor distribution in tested tissues. 
There is some evidence to suggest, however, that clenbuterol is more selective for β2-AR 
though it is an agonist for the other subtypes as well (Sillence et al., 1991).  
Clenbuterol Alters Body Composition 
 Oral administration of clenbuterol increased protein:fat ratio in carcasses of 
several species including cattle, sheep and chickens (Baker et al., 1984; Rehfeldt et al., 
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1997; Ricks et al., 1984). Additionally, clenbuterol attenuated muscle atrophy caused by 
hind-limb unloading (Yimlamai et al., 2005), denervation (Zeman et al., 1987), and 
glucocorticoid treatment (Pellegrino et al., 2004). Skeletal muscle protein accretion is 
increased by clenbuterol treatment by two actions: first, a transient increase in muscle 
protein synthesis (Maltin et al., 1989) and second, a more prolonged decrease in muscle 
protein degradation (Bohorov et al., 1987; Reeds et al., 1986). Clenbuterol treatment 
causes slow to fast transition of fiber types (Oishi et al., 2004). 
In mice, clenbuterol increases muscle hypertrophy mediated by β2-AR (Hinkle et 
al., 2002) leading to downstream activation of protein kinase A as described above. 
However, β2-AR binding by clenbuterol also activates the Giα-Gβγ-phosphatidylinositol 
3-kinase (PI3K) /Akt signaling pathway resulting in transiently increased 
phosphorylation of eukaryotic initiation factor (eIF)4E binding protein-1 and p70S6k  
(Sneddon et al., 2001). Treatment with rapamycin, the specific inhibitor of m-TOR,  
reduced clenbuterol-induced muscle hypertrophy and blocked clenbuterol-induced 
muscle sparing during hindlimb unloading (Kline et al., 2007). Regarding the more long-
term reduction in protein degradation, clenbuterol treatment reduced activation of 
ubiquitin-proteosome (Yimlamai et al., 2005).  
In addition to increasing protein accretion, clenbuterol administration reduces fat 
accumulation. As previously detailed, β-AR binding leads to a signaling cascade resulting 
in protein kinase A activation which in turn phosphorylates hormone-sensitive lipase, 
responsible for lipolysis in adipocytes. Protein kinase A also phosphorylates acetyl co-A 
carboxylase, thereby inhibiting the first step of fatty acid synthesis. As a consequence, 
clenbuterol reduces adipocyte number and size in cattle (Miller et al., 1988) and overall 
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fat pad weight in mice (Choo et al., 1992; Page et al., 2004). Others have suggested that 
clenbuterol induces adipocyte apoptosis as measured by DNA fragmentation, but further 
study is warranted (Page et al., 2004).  
 
High-fat Diet-induced Obesity 
Human obesity, defined as a body mass index in excess of 30 kg/m2, is increasing 
in developed nations, and in the United States, over 30% of adults are considered obese 
(Ogden et al., 2006). Thus, models to study obesity are important and ways to reduce fat 
accumulation and offset negative health consequences associated with excess weight and 
body fat are sought. Associated with obesity, though sometimes occurring independently, 
is metabolic syndrome, a cluster of risk factors for cardiovascular disease of which 
insulin resistance is thought to be an underlying cause (Kahn et al., 2005). Skeletal 
muscle is the largest tissue responsible for insulin-stimulated glucose uptake (DeFronzo 
et al., 1985), and thus, is also at the root of insulin resistance. In skeletal muscle, insulin 
signaling leads to translocation of GLUT-4 receptors to the cell surface where they 
transport glucose into cells. Insulin resistance, or the failure of insulin to stimulate 
glucose uptake, is related to obesity.  
The overall purpose of adipose tissue is to store fuel in times of food excess to 
increase survivability during times of food shortage. Diet-induced obesity disrupts lipid 
storage by increasing lipids in tissues other than adipose. If a normal individual consumes 
too many calories, their adipocytes expand and produce more leptin. This leptin 
encourages fatty acid oxidation, decreased storage of lipids in tissues, and helps to 
maintain a normal level of lipids in lean tissue. However, chronic overconsumption leads 
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to a build-up of lipid in lean tissues including muscle partly because efficiency of fatty 
acid uptake is increased in skeletal muscle of animals fed diets high in fat (Hegarty et al., 
2002).  
Insulin resistance may be related to the increased lipid content of muscle cells in 
high-fat diet-induced obesity. In muscle tissue, palmitoyl coA, a fatty acid, combines 
with serine to produce ceramide. Increased ceramide decreases phosphorylation of insulin 
receptor substrate 1 (IRS-1) thereby reducing its’ activity and decreasing insulin 
signaling (Kanety et al., 1996). Independent of ceramide, fatty acyl coA and 
diacylglycerols lead to inhibitory phosphorylation of IRS-1 (Yu et al., 2002), which also 
reduces insulin signaling. The formation of ceramide is also toxic to muscle cells as 
evidenced by increased apoptosis (Turpin et al., 2006). This lipotoxicity is not limited to 
muscle cells; ceramide also induces apoptotic factors in pancreatic β-cells responsible for 
insulin production. This loss of insulin producing capability further decreases insulin 
signaling in obesity.  
Increased circulating levels of triglycerides, insulin and glucose, and increased 
liver fat content are also all correlated with metabolic syndrome (Marchesini et al., 2003; 
Taskinen, 2003). Leptin levels are reflective of lipid content in mice, and increased leptin 
is associated with obesity (Frederich et al., 1995). Though the action of leptin is to 
increase metabolic rate and decrease food intake, increased leptin levels in obesity do not 
result in these actions indicating leptin resistance (Lin et al., 2000).  Conversely, 
adiponectin sensitizes cells to insulin and is decreased in obese or insulin resistant 
individuals (Yamauchi et al., 2001). Thus, aberrations in leptin, insulin and adiponectin 
all contribute to the obesigenic state and related insulin resistance.  
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In rodents, high concentrations of dietary fat are associated with increased weight 
gain and body fat content (West et al., 1992) similar to human obesity. Increased weight 
gain is due in part to hyperphagia, or an overconsumption of calories. However, in 
studies where intake was controlled, the weight and body fat of animals are still increased 
(West and York, 1998). Rats fed isocalorically with an increasing amount of calories 
from fat showed increased body fat in a dose-dependent manner (Boozer et al., 1995) 
suggesting that fat in the diet, in particular, contributes to obesity.  
 Not all rodents, however, are equally susceptible to diet-induced obesity. Mice of 
the C57BL/6J inbred strain are particularly sensitive to high-fat diet-induced obesity 
(Surwit et al., 1995). When diets with high sucrose and high fat were fed for 4 months, 
mice exhibited increased weight gain, fat pad weight and adipocyte hyperplasia, most 
evident in mesenteric fat. However, increases were more pronounced in mice on 
combined high fat/high sucrose diets than those on low fat/ high sucrose diets despite the 
diets being isocaloric. Furthermore, mice of the same strain fed isocalorically with 
animals on a lower fat diet also  had increased body fat and impaired glucose metabolism 
(Petro et al., 2004). These findings illustrate that obesity-induction by high fat diets 
results from both increased caloric consumption and increased fat consumption  
Furthermore, the use myostatin null mice of a C57BL/6J inbred background seem the 
most appropriate model for exploring the susceptibility of myostatin null mice to high-fat 
diet induced obesity.  
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CHAPTER 2 
THE MYOSTATIN NULL MUTATION AND CLENBUTEROL 
ADMINISTRATION ELICIT ADDITIVE EFFECTS IN MICE 
 
Abstract 
In mice, the myostatin null mutation and treatment with clenbuterol both increase muscle 
growth and decrease fat mass. Our objective was to determine if mechanistic overlap 
exists by administering clenbuterol to myostatin null mice.  Male myostatin null and wild 
type mice of similar genetic backgrounds received either 0 (control) or 20 ppm 
clenbuterol in tap water free choice for 14 days.  Several traits were measured to estimate 
muscle and fat growth. The myostatin null mutation resulted in increased body and empty 
carcass weight, increased muscle weights, and decreased fat pad weights. Fat content was 
reduced and protein content increased in the empty carcasses of myostatin null mice. 
Similarly, treatment with clenbuterol resulted in increased body and empty carcass 
weight, increased muscle weights and reduced fat pad weights. Fat content of empty 
carcasses and viscera was reduced and protein content of empty carcasses was increased 
with clenbuterol treatment. A significant interaction of genotype and clenbuterol 
treatment would indicate an altered responsiveness of myostatin null mice to clenbuterol. 
However, only the weight of gastrocnemius muscles exhibited a significant (P = 0.01) 
interaction of genotype and clenbuterol treatment, indicating myostatin null mice were 
less responsive to clenbuterol compared with wild type mice. Thus, for all other traits, the 
impact of myostatin null mutation and clenbuterol treatment were completely additive. 
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These data suggest that disruption of myostatin function does not alter the response of 
mice to β-adrenergic agonists.  
Introduction 
Several strategies are available to alter muscle and fat growth in animals with the 
ultimate goal of increasing efficiency of livestock production. The use of β-adrenergic 
agonists (βAA) to increase muscle mass and decrease fat mass in several species is well-
established (Beermann, 2002; Mersmann, 1998; Ricks et al., 1984). Clenbuterol, though 
not approved for commercial use in livestock, increases muscle growth in mice and other 
species (Yang and McElligott, 1989). Another strategy to alter animal growth is to 
introduce mutations into the myostatin (Mstn) gene as occurs naturally in double-muscled 
cattle. These cattle exhibit striking increases in muscle growth and reductions in fat mass 
(Grobet et al., 1997; McPherron and Lee, 1997; Kambadur et al., 1997; Grobet et al., 
1998). Transgenic Mstn null mice can be used as a model for this effect as this species 
also exhibits increased muscularity and decreased fat deposition (McPherron et al., 1997; 
McPherron and Lee, 2002). Furthermore, disruption of Mstn function is thought to confer 
resistance to several types of obesity development (McPherron and Lee, 2002; Zhao et 
al., 2005).  
Though the results of Mstn disruption are similar to those of treatment with βAA, 
namely increased muscle deposition and decreased fat mass, the proposed mechanisms of 
each are quite different. Clenbuterol is a selective β-2 agonist (Hinkle et al., 2002) and 
results in alterations in protein deposition possibly through changes in protein synthesis 
or degradation rates, but a specific mechanism is, as of yet, unclear.  Clenbuterol has also 
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been shown to reduce adipose tissue mass through apoptosis of adipocytes (Page et al., 
2004). In contrast to βAA, Mstn functions in cell cycle regulation with the loss of Mstn 
function resulting in increased proliferation of embryonic and fetal myoblasts causing 
hyperplasia (Thomas et al., 2000) and greater activity in satellite cells contributing to 
increased hypertrophy (McCroskery et al., 2003). Mechanisms behind the reduced 
adiposity of Mstn null mice and their resistance to obesity are less clear. It may simply be 
a result of increased energy needs of muscle tissue, thus reducing the energy available for 
fat deposition, or may result from altered adipocyte function due to the loss of Mstn 
activity.  
Due to the disparate mechanisms of increased muscle and reduced fat growth 
from alteration of Mstn or the use of βAA, we hypothesized that the Mstn null mutation 
would not alter responsiveness to βAA treatment, though such an interaction has not 
previously been tested.  It is possible, however, that increased muscle growth due to loss 
of Mstn function is so extensive that further increases are not possible, and in this 
scenario, one would expect that Mstn null mice would be unresponsive to clenbuterol 
treatment. Simply put, muscles of Mstn null animals may have reached their maximal 
size and cannot grow any larger. To test this hypothesis, clenbuterol was administered to 
Mstn null and wild type mice. Several measures of muscle mass and adiposity were used 
to determine the impact of clenbuterol treatment on muscle and fat growth in these mice.  
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Materials and Methods 
 Animals, Observations and Materials 
Five-week-old male wild type (n=32) and Mstn null (n=24) mice from an internal 
C57BL6/J colony were housed singly in solid-bottom cages and given ad libitum access 
to pelleted rodent chow (Teklad F6 rodent diet, Harlan, Indianapolis, IN) and water. 
Ambient room temperature was maintained with a 12 hour light/dark cycle. Mice 
received free access to either tap water (control) or tap water with 20 ppm clenbuterol 
(Sigma-Aldrich, St. Louis, MO, item # C5423) for two weeks. Body, food and water 
weights were all measured on day 1 (trial initiation), day 8, and day 15 (trial conclusion). 
Efficiency was calculated by dividing weight gain by food intake. Animals were 
sacrificed on day 15 by carbon dioxide asphyxiation and cervical dislocation. All animal 
procedures were approved by the University of Illinois Institutional Animal Care and Use 
Committee.  
Dissection and Proximate Composition 
A subset of mice (12 wild type and 10 Mstn null) were dissected to estimate 
muscle and fat deposition. Inguinal, retroperitoneal, and epididymal fat pads were 
harvested and weighed. Skin, feet, head, tail and viscera were removed and the remaining 
carcass (i.e., empty carcass) was weighed. Tibialis anterior, triceps brachii, biceps 
femoris and gastrocnemius muscles were removed from the right side and weighed.  
Proximate composition of empty carcass and viscera were determined on a subset 
of mice (20 wild type and 14 Mstn null) to estimate muscle and fat deposition. Empty 
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carcasses and viscera were weighed, dried in a 60ºC oven for at least 48 hours, re-
weighed and ground with a commercial coffee grinder (SmartGrind, Black and Decker, 
Towson, MD). Ground samples were then dried to a constant weight in a 110ºC oven. 
Lipid content was calculated by weight difference after extraction with 4:1 
chloroform:methanol solution (Novakofski et al., 1989). Crude protein content (nitrogen 
x 6.25) was determined by the combustion method (AOAC, 2000; method 990.03) with a 
Leco model FP2000 (Leco Corp., St. Joseph, MI), using EDTA as an internal standard. 
Statistical Analysis 
Statistical analyses were performed using SAS version 9.1 (SAS Institute Inc, 
Cary, NC). Analysis of variance was used to determine the significance of genotype, 
clenbuterol treatment and their interaction employing the Mixed procedure of SAS. For 
body weight, analysis included repeated measures with an autogressive 
variance/covariance structure. Data are presented as lsmeans ± S.E.M with P-values for 
the main effects of genotype, clenbuterol treatment and their interaction. Of particular 
interest is the interaction term, as lack of significant interaction indicates that main effects 
are completely additive, and response to clenbuterol treatment is similar between the two 
genotypes.  
Results 
 Body Weight, Food and Water Intake, Efficiency and Dosage 
 There were no differences in body weight between the genotypes on day 1. After 
7 days on trial, however, Mstn null mice were 1.8 g heavier (P < 0.01) than wild type 
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mice and mice treated with clenbuterol were 1.3 g heavier (P = 0.01) than control (Figure 
1). These effects continued until the end of the trial (d 15) when Mstn null mice were 3.5 
g heavier (P < 0.01) than wild type mice and clenbuterol treatment increased (P = 0.02) 
body weight by 1.3 g. There was no interaction (P > 0.64) between genotype and 
clenbuterol treatment for body weight at any time point. Similarly, gain (mg/d) was 
higher (P < 0.01) in Mstn null mice compared with wild type and was increased (P < 
0.01) by clenbuterol treatment (Table 2.1). Food intake (g/d) was also higher (P = 0.01) 
in Mstn null compared with wild type but was not impacted by clenbuterol treatment (P = 
0.11). Efficiency (mg gain: g food), however, was higher (P < 0.01) in Mstn null mice 
compared with wild type and was also increased (P = 0.02) by clenbuterol treatment. 
There was no interaction of genotype and clenbuterol treatment for gain, food intake or 
efficiency (P > 0.21). Water intake was increased (P < 0.01) in clenbuterol-treated mice 
compared with control but was not impacted by genotype. Given the water intake of these 
mice, clenbuterol intake was estimated to be 0.148 mg/d for wild type and 0.135 mg/d for 
Mstn null mice.  
Proximate Composition of Carcass and Viscera 
 To establish the composition of increased body weight in Mstn null mice and in 
mice treated with clenbuterol, proximate analyses of the empty carcass and the viscera 
were performed (Table 2.2). Empty carcass weight was approximately 4 g higher (P < 
0.01) in Mstn null mice compared with wild type and was increased (P < 0.01) 
approximately 1 g by clenbuterol treatment. There was no interaction of genotype and 
clenbuterol treatment for empty carcass weight (P = 0.99). Furthermore, indicative of 
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increased muscle growth, protein content of empty carcasses was 0.5 percentage units 
higher (P = 0.04) in Mstn null mice compared with wild type, and was increased 0.7 
percentage units (P < 0.01) by clenbuterol treatment. Conversely, fat content of the empty 
carcass was 2 percentage units lower (P < 0.01) in Mstn null mice compared with wild 
type, and was decreased 1.3 percentage units (P < 0.01) by clenbuterol treatment, 
indicative of lower fat deposition. Weight of viscera was not different between the 
treatment groups, but fat content of the viscera was decreased 2 percentage units (P < 
0.01) by clenbuterol treatment. For all proximate composition traits, there was no 
interaction of genotype and clenbuterol treatment (P > 0.24).  
Muscle and Fat Pad Weights 
To further establish the concept of increased muscle and decreased fat deposition 
in Mstn null mice and mice treated with clenbuterol, several muscles and fat pads were 
dissected and weighed (Table 2.3); these data were normalized to day 15 body weights 
(Figure 2.1). Muscle weights of Mstn null mice were 1.5 – 2 times heavier (P < 0.01) 
than those of wild type mice. Clenbuterol treatment also increased the weight of tibialis 
anterior, triceps brachii, and gastrocnemius muscles (P < 0.05) but did not alter the 
weight of the bicep femoris. For the gastrocnemius, however, there was an interaction (P 
= 0.01) of genotype and clenbuterol treatment indicating a decreased response to 
clenbuterol treatment in Mstn null mice. In wild type mice, gastrocnemius weight was 
increased 0.12 percentage units (4.5 mg) while in Mstn null mice it was increased only 
0.07 percentage units (2.8 mg).  
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Inguinal fat pad weight was not altered by genotype or clenbuterol treatment. 
Retroperitoneal and epididymal fat pad weights were lowered (P < 0.01) 0.08 and 0.47 
percentage units, respectively, in Mstn null mice compared with wild type and were also 
reduced (P < 0.05) by clenbuterol treatment. The interaction of genotype and clenbuterol 
treatment was tending towards significance (P = 0.12) for the epididymal fat pad. Similar 
to the gastrocnemius muscle, fat pads from Mstn null mice were not as responsive to 
clenbuterol as wild type mice. Epididymal fat pad weight was decreased 0.48 percentage 
units in wild type mice while it was only reduced 0.14 percentage units in Mstn null 
mice.  
Discussion 
Both the Mstn null mutation and clenbuterol administration result in increased 
muscle mass and decreased fat mass in animals, including mice. Though phenotypic 
outcomes are similar, the mechanisms by which each impacts these tissues are quite 
different. Therefore, we hypothesized that myostatin null mice would respond to 
clenbuterol treatment similarly to wild type mice. This interaction of βAA treatment and 
the loss of myostatin function has not previously been reported. Although the extreme 
muscling phenotype observed in Mstn null animals may represent near maximal muscle 
mass, it is imperative to establish whether the Mstn null mutation and clenbuterol 
treatment elicit mutually exclusive effects. 
Disruption of Mstn functionality results in increased muscle mass, decreased 
adiposity and improved efficiency (McPherron and Lee, 1997; McPherron and Lee, 2002; 
Mitchell and Wall, 2007; Szabo et al., 1998;  Yang et al., 2001). Mstn null mice often 
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exhibit muscle weights 1.5- to 2-times greater than their wild type counterparts 
(McPherron et al., 1997) while weights of individual fat pads are reduced (McPherron 
and Lee, 2002). In our experiment, the Mstn null mutation resulted in the expected 
phenotype. Body weight and empty carcass weight were both increased, 3.5 and 4 g, 
respectively, in Mstn null mice compared with wild type. The majority of weight gain 
was either in muscle or bone tissue as indicated by the large increase in empty carcass 
weight. While viscera weight was not reduced in Mstn null mice compared with wild 
type, it did constitute a smaller proportion of total body mass. This finding is similar to 
reports of smaller organ sizes in double-muscled cattle (Arthur, 1995), the mechanism of 
which is unclear.  
Food intake was also increased in Mstn null mice compared with wild type mice 
contrary to other reports (Lin et al., 2002; McPherron and Lee, 2002). Compared with 
previous research, mice in our study consumed less food overall. This may reflect slight 
site-to-site and strain-to-strain differences in Mstn null mice. However, efficiency 
(gain:food) was increased in Mstn null mice compared to wild type indicating that, 
though they consumed more food than their wild type counterparts, Mstn null mice were 
still more efficient at converting nutrients into body tissue. As others have shown 
increased weight gain in Mstn null mice despite a lack of change in food intake, increased 
efficiency was expected.  
Muscle mass was increased in Mstn null mice compared with wild type. Weights 
of individual muscles were 1.5- to 2-times higher in Mstn null mice compared with wild 
type similar to previous reports (McPherron et al., 1997). Further evidence of increased 
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muscularity in Mstn null mice included the 0.5 percentage unit increase in empty carcass 
protein compared with wild type. Conversely, fat deposition was reduced by the Mstn 
null mutation. We observed a 2 percentage unit decrease in empty carcass fat, and a 
reduction in fat pad weight of 33-38% in Mstn null compared with wild type mice, 
similar to the findings of McPherron and Lee (2002). There was no observed decrease in 
visceral fat content in Mstn null mice. From these data, we conclude that the loss of Mstn 
function increased muscularity and decreased adiposity as expected.  
Clenbuterol treatment, similar to several other βAA, improves feed efficiency, 
increases protein accretion and therefore muscle mass, and decreases fat mass 
(Beermann, 2002; Mersmann, 1998; Ricks et al., 1984; Yang and McElligott, 1989). As a 
selective β-2 agonist (Hinkle et al., 2002), clenbuterol likely alters protein degradation 
(Reeds et al., 1986; Yimlamai et al., 2005) to increase protein accretion but may also 
alter protein synthetic rates. Alternatively, reductions in fat mass may result from energy 
repartitioning or direct effects on adipocyte apoptosis (Page et al., 2004).  In our 
experiment, clenbuterol treatment increased muscle deposition and reduced fat mass as 
expected. Body and empty carcass weight were increased 1.3 g and 1 g, respectively, in 
clenbuterol treated mice compared with control. The large proportion of body weight 
gain retained in the empty carcass was indicative of increases in muscle and bone mass as 
opposed to increased visceral or fat mass. Previous reports have indicated that heart 
muscle weight is increased with clenbuterol treatment (Cubria et al., 1998; Petrou et al., 
1995). Thus, we would have expected increased viscera weight, but in our study, viscera 
weight was unchanged by clenbuterol treatment. It is possible that cardiac hypertrophy 
occurred in our study but was unnoticeable as the entire visceral mass, and not the heart 
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alone, was weighed.  Increased muscularity of clenbuterol-treated mice, as suggested by 
increased empty carcass weight, was also observed. Muscle weights of clenbuterol 
treated mice were 1.2-times heavier than those of control mice. Clenbuterol treatment 
also resulted in a 0.7 percentage unit increase in empty carcass protein content. 
Furthermore, clenbuterol treatment reduced fat mass as expected. Fat pad weight was 
decreased 23-25% and empty carcass fat content was reduced by 1.3 percentage units. In 
contrast to the lack of effect due to the Mstn null mutation, visceral fat content was also 
lowered by clenbuterol treatment. Therefore, we conclude from these data that 
clenbuterol treatment increased muscle growth and decreased fat mass similar to previous 
reports.  
Given that results of both clenbuterol treatment and Mstn null mutation were as 
expected, we were able to determine the validity of our hypothesis that Mstn null mice 
respond similarly to wild type mice when administered clenbuterol.  A lack of significant 
interaction between genotype and clenbuterol treatment would, therefore, validate our 
hypothesis. The only trait with a significant interaction was gastrocnemius weight. The 
increase in gastrocnemius muscle weight from clenbuterol treatment was less in Mstn 
null mice than wild type. There was also a tendency for the decrease in epididymal fat 
with clenbuterol treatment to be less in Mstn null mice than in wild type. Thus, in these 
instances, it is possible that the phenotypic effects of the Mstn null mutation were so 
extreme (i.e., greatly increased weight of the gastrocnemius and reduced weight of the 
epididymal fat pad), that additional changes from clenbuterol treatment were minimal. 
However, both of these tissues did experience numerical changes in weight in Mstn null 
mice treated with clenbuterol, indicating the capacity to respond was intact but somewhat 
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blunted. For all other traits measured, there was no significant interaction, indicating the 
effect of Mstn null mutation and clenbuterol treatment were completely additive. Thus, 
Mstn null mice experienced increased muscle deposition and reduced fat mass due to 
clenbuterol treatment to the same extent as wild type mice.  
Given their diverse mechanisms of action, it is logical to conclude that βAA 
treatment and Mstn disruption would not interact. However, with identification of Mstn 
(McPherron et al., 1997) and its association to the well-characterized double-muscling 
phenotype in cattle (Grobet et al., 1997; Kambadur et al., 1997; McPherron and Lee, 
1997), the idea of a muscle chalone—an inhibitory molecule secreted by the muscle 
which ultimately governed its size (Bullough, 1962; Bullough, 1965)—was revived (Lee 
and McPherron, 1999). If Mstn was this muscle chalone, the loss of its function to 
regulate the size of muscle independent of other factors would allow muscle to grow to 
its maximal possible size. The “doubling” observed in mice and cattle lacking Mstn 
activity certainly seems to represent a type of maximal size which muscle could attain 
and unresponsiveness to other means of increasing muscle growth would be expected. 
The working hypothesis that Mstn was the elusive muscle chalone, however, has been 
disproven as supported by evidence from our study and others. Whereas the increase in 
muscle mass of Mstn null mice is large, there is now sufficient evidence to suggest that 
maximal muscle growth has not yet been attained. Mice with postnatal transgenic 
overexpression of Mstn propeptide fed high-fat diets exhibit increased muscle growth 
compared to similar transgenic mice fed lower fat diets (Yang and Zhao, 2006). 
Furthermore, follistatin overexpression in Mstn null mice also results in increased muscle 
growth compared with normal Mstn null mice—nearly a quadrupling of muscle mass 
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compared with wild type mice (Lee, 2007). Our study, in which Mstn null mice exhibited 
increased muscle growth following clenbuterol treatment, provides additional evidence 
contradicting the hypothesis that Mstn may serve as a muscle chalone and indicates that 
Mstn null mice respond to treatment with βAA similar to wild type mice. Given the 
additive effects of Mstn and clenbuterol, it may be possible to exploit these apparently 
distinct modes of action to control muscle mass in animals.  
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Figure 2.1. Body weight during clenbuterol administration (dashed lines) to wild type (■) 
and myostatin null (▲) mice with standard errors displayed.  
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Table 2.1. Effects of genotype (G) and clenbuterol treatment (T) and their interaction (GxT) on daily gain, food intake, water 
consumption and clenbuterol dose of wild type and myostatin null mice1 
  Wild Type  Myostatin Null  P-value 
  Control Clenbuterol  Control Clenbuterol  G  T GxT 
Number of mice 16 16 11 13 
Gain (mg/d) 189 ± 27.2 304 ± 27.2 419 ± 32.8 497 ± 30.2 <0.01 <0.01 0.53 
Food intake (g/d) 3.5 ± 0.16 3.6 ± 0.16 3.8 ± 0.20 4.2 ± 0.18 0.01 0.11 0.33 
Efficiency (mg/g)2 562 ± 10.1 958 ± 10.1 111 ± 12.2 123 ± 11.2 <0.01 0.02 0.21 
Water intake (ml/d) 6.1 ± 0.27 7.4 ± 0.27 5.9 ± 0.32 6.7 ± 0.30 0.16 <0.01 0.42 
Clenbuterol intake (mg/d)3 .  0.148 ± 0.005   . 0.135 ± 0.006   .  . .  
1 Mice were given ad libitum access to tap water with 20 ppm clenbuterol (Clenbuterol) or without (Control). 
Values are lsmeans ± S.E.M. 
2Efficiency was calculated by dividing weight gain by food intake.  
3P-values are not provided for clenbuterol intake as it was a numerical calculation based on water intake and a 
dose of 20 parts per million clenbuterol in the water.  
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Table 2.2. Effects of genotype (G) and clenbuterol treatment (T) and their interaction (GxT) on empty carcass weight and composition 
and viscera weight and composition of wild type and myostatin null mice1 
 Wild Type  Myostatin Null  P-value 
  Control Clenbuterol  Control Clenbuterol  G  T GxT 
Number of mice 15 15 11 12 
Empty carcass weight (g)2 8.8 ± 0.29 10 ± 0.29 12.9 ± 0.34 14.1 ± 0.32 <0.01 <0.01 0.99 
Number of mice 10 10 6 8 
Empty carcass fat (%) 7.1 ± 0.30 5.4 ± 0.30 4.7 ± 0.38 3.8 ± 0.33  <0.01 <0.01 0.24 
Empty carcass protein (%) 20.9 ± 0.22 21.7 ± 0.22 21.5 ± 0.28 22.1 ± 0.24 0.04 0.01 0.69 
Viscera weight (g) 6.0 ± 0.19 6.0 ± 0.19 6.1 ± 0.24 5.6 ± 0.21 0.52 0.17 0.27 
Viscera fat (%) 9.8 ± 0.47 8.3 ± 0.47  10.7 ± 0.6 8.2 ± 0.52  0.49 <0.01 0.40 
1 Mice were given ad libitum access to tap water with 20 ppm clenbuterol (Clenbuterol) or without (Control). 
Values are lsmeans ± S.E.M. 
2 Empty carcass is carcass remaining after skin, head, tail, feet and viscera were removed.  
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Table 2.3. Effects of genotype (G) and clenbuterol treatment (T) and their interaction (GxT) on muscle and fat pad weights (% of body 
weight) of wild type and myostatin null mice1 
 
  Wild Type  Myostatin Null  P-value 
  Control Clenbuterol  Control Clenbuterol  G  T GxT 
Number of mice 6 6 5 5 
Muscles  
     Tibalis Anterior 0.20 ± 0.015 0.23 ± 0.015 0.37± 0.016 0.40 ± 0.016 < 0.01 0.03 0.94 
     Triceps Brachii 0.38 ± 0.020 0.43 ± 0.020 0.57 ± 0.022 0.67 ± 0.022 < 0.01 < 0.01 0.26 
     Biceps Femoris 0.51 ± 0.044 0.58 ± 0.044 0.72 ± 0.048 0.71 ± 0.048 < 0.01 0.58 0.42 
     Gastrocnemius 0.51 ± 0.010 0.63 ± 0.010 0.80 ± 0.011 0.87 ± 0.011 < 0.01 < 0.01 0.01 
Fat Pads 
     Inguinal 0.89 ± 0.071 0.72 ± 0.071 0.78 ± 0.078 0.71 ± 0.078 0.45 0.13 0.55 
     Retroperitoneal 0.23 ± 0.025 0.16 ± 0.025 0.13 ± 0.027 0.09 ± 0.027 < 0.01 0.05 0.53 
     Epididymal 1.40 ± 0.101 0.92 ± 0.101 0.76 ± 0.111 0.62 ± 0.111  < 0.01 < 0.01 0.12 
1 Mice were given ad libitum access to tap water with 20 ppm clenbuterol (Clenbuterol) or without (Control). 
Values are lsmeans ± S.E.M. 
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CHAPTER 3 
HIGH-FAT DIET-INDUCED OBESITY IN MYOSTATIN NULL MICE 
 
Abstract 
High-fat diet-induced obesity is one model to examine obesity in humans, and several 
mutations have been identified which confer some degree of resistance to obesity 
development. The objective of this experiment was to examine the resistance to diet-
induced obesity of myostatin (Mstn) null mice and determine if genes involved in 
thermogenesis were altered in these mice. Four-week-old male Mstn null and wild type 
mice were given ad libitum access to diets with 10 or 60% kcal from fat for 12 weeks. 
Glucose tolerance was determined after 0, 4, 8 and 12 weeks on diet. Body composition, 
muscle and fat pad weights, as well as other markers of metabolic syndrome were 
recorded and mRNA expression of several genes was examined in muscle, fat and liver. 
High-fat fed mice consumed more calories and deposited weight and calories more 
efficiently than control mice. After 12 weeks of high-fat feeding, body weight, body fat, 
fat pad weight, fasting blood glucose, serum insulin and leptin expression in adipose 
tissue were increased in both wild type and Mstn null mice. However, for all these 
parameters, the increase in Mstn null mice was less pronounced than in wild type mice 
indicating partial resistance to fat gain with excessive caloric consumption.  While some 
genes involved in thermogenesis were increased in Mstn null mice, it does not appear that 
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increased thermogenesis accounts for differences in body fat content between Mstn null 
and wild type mice.  
Introduction 
Myostatin (Mstn), a member of the TGF-β superfamily, has been well-
characterized as a negative regulator of muscle growth. Mutations that inactivate or 
inhibit  Mstn result in hypermuscularity in several species including: mice (Lee and 
McPherron, 1999; Marcq, 1998; McPherron et al., 1997; Yang and Zhao, 2006), cattle 
(Grobet et al., 1997; Grobet et al., 1998; Kambadur et al., 1997; McPherron and Lee, 
1997), dogs (Mosher et al., 2007) and humans (Schuelke et al., 2004). For example, Mstn 
mutations are responsible for the “double-muscled” phenotype long observed in Belgian 
Blue and Piedmontese cattle (Kambadur et al., 1997). Increased muscle mass results from 
both hyperplasia and hypertrophy, and muscles from affected individuals can have nearly 
twice as many muscle fibers as normal individuals.   
In addition to its role in muscle, a biological function of Mstn has been suggested 
in adipose tissue. Body fat accumulation is decreased in Mstn null mice (McPherron and 
Lee, 2002) when compared with wild type mice of the same chronological age. This 
reduction in body fat is a manifestation of reductions in both adipocyte number and size 
in Mstn null mice (McPherron and Lee, 2002) and is accompanied by an increased 
respiratory exchange rate and enhanced utilization of carbohydrates (Guo et al., 2009). 
Furthermore, this reduced adiposity is coupled with a reduction of adipogenic proteins in 
fat cells including PPARγ and C/EBPα, markers of terminal differentiation in adipocytes 
(Lin et al., 2002a).  
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In several rodent models of obesity, Mstn null mice have proven to be less 
sensitive to obesity induction. Diets high in fat cause overeating and induce obesity in 
mice (West and York, 1998; Woods et al., 2003), especially in the obesity-prone 
C57BL6/J inbred strain (Surwit et al., 1995). However, several authors have 
demonstrated a reduced propensity for fat gain of Mstn null mice fed high-fat diets (Guo 
et al., 2009; Hamrick et al., 2006). Similarly, mice with a transgenic overexpression of 
the Mstn propeptide fed similar diets were also resistant to high-fat diet-induced obesity 
(Yang and Zhao, 2006; Zhao et al., 2005). When incorporated into mice with genetic 
forms of obesity (agouti yellow, ob/ob), Mstn null alleles provided protection against the 
development of obesity and insulin resistance (McPherron and Lee, 2002).  Taken 
together, these data suggest that inactivation or inhibition of Mstn results in resistance to 
fat accretion.   
The direct impact of Mstn on adipocytes has recently been explored. Myostatin, 
the Mstn receptor (activin type 2B receptor) and one Mstn inhibitor were expressed in 
adipose tissue though at levels much lower when compared with skeletal muscle (Allen et 
al., 2008). Myostatin expression increased in adipose tissue with high-fat feeding and in 
ob/ob mice. In other work, mice with transgenic overexpression of Mstn in adipocytes 
were resistant to developing insulin resistance and obesity induced by high-fat feeding 
(Feldman et al., 2006). These results indicate that Mstn may be important in adaptation of 
adipose tissue to limit its own growth and resist the development of obesity.  However, if 
Mstn plays a role in resisting obesity development, it is plausible that Mstn null mice 
would be more, and not less, sensitive to obesity induction. Thus, the role Mstn plays in 
obesity development is unclear. Therefore, the objective of this study was to determine 
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the response of Mstn null mice to consumption of a very high-fat diet and elucidate the 
mechanism of obesity resistance in these animals.  
Materials and Methods 
 Animals, Observations and Materials 
All animal procedures were approved by the University of Illinois Institutional 
Animal Care and Use Committee.  
Replicate 1: Four-week-old male Mstn null (n=21) and wild type mice (n=22) from an 
internal C57BL6/J colony were genotyped by PCR-based genotyping described by 
McPherron et al. (1997). Mice were housed singly in solid-bottom cages and given ad 
libitum access to pelleted rodent chow and water. Ambient room temperature was 
maintained with a 12 hour light/dark cycle. Mice were assigned to either a normal or 
high-fat diet obtained from Research Diets, Inc. (New Brunswick, NJ). The high fat diet 
(Product number: D12492) contained 5.24 kilocalories per gram of food while the normal 
low fat diet (Product number: D12450B) contained 3.85 kilocalories per gram of food. 
Lard was the fat source for both diets.  Body, food and water weights were all measured 
at the initiation of the trial and then weekly for 12 weeks.  
Replicate 2: An additional set of four-week-old male Mstn null mice from the internal 
colony (n=10) and wild type mice (n=10) obtained from Jackson Labs (Bar Harbor, ME) 
were assigned to normal and high fat diets. These mice were housed in groups of 5 
animals per cage with environmental conditions identical to those described above and 
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given ad libitum access to food and water. Body weight was measured weekly on 
individual mice for 12 weeks.  
Animals from both replicates were sacrificed after 12 weeks of dietary treatment 
(16 weeks of age) by carbon dioxide asphyxiation and cervical dislocation after a 16 h 
fast. Blood, collected by cardiac puncture, was allowed to coagulate, and serum was 
obtained after centrifugation at 14,000xg for 10 minutes at 4ºC and stored at -80ºC.   
Glucose Tolerance Test 
 In the first replicate, a single glucose tolerance test was performed at 
approximately 16 weeks of age (2 days prior to sacrifice). Food was removed 16 hour 
prior to the glucose tolerance test. Mice were weighed and a small drop of blood was 
obtained from the end of the tail. Blood glucose was determined using an Accu-chek 
Active glucose meter (Roche Diagnostics Corp., Indianapolis, IN). Mice were then 
administered 1 mg dextrose/g body weight by intraperitoneal injection. Blood glucose 
was measured at 30, 60, 90 and 120 min post-injection. In the second replicate, glucose 
tolerance tests were performed as described above at 8, 12 and 16 weeks of age. Area 
under the curve was calculated using the trapezoidal method with the baseline of each 
mouse subtracted.  
Dissection, Sample Collection and Proximate Composition 
All mice were dissected to estimate muscle and fat deposition. Inguinal, 
retroperitoneal, subscapular and epididymal fat pads were collected and weighed. Skin, 
feet, head, tail and viscera were removed and the remaining carcass (i.e., empty carcass) 
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was weighed. Tibialis anterior, triceps brachii, biceps femoris and gastrocnemius muscles 
were removed from the right side and weighed. From the first replicate, sub-samples of 
liver, epididymal fat pad, gastrocnemius muscle and bicep femoris muscle were flash-
frozen in liquid nitrogen and stored at -80ºC.  
Mice from the second replicate were used to estimate body composition. Fat and 
protein content were determined from the skin, carcass, viscera and liver. Samples were 
weighed and dried to a constant weight in a 60ºC oven, re-weighed and ground with a 
commercial coffee grinder (SmartGrind, Black and Decker, Towson, MD). Ground 
samples were then dried to a constant weight in a 110ºC oven. Lipid content was 
calculated by weight difference after extraction with 4:1 chloroform:methanol solution 
(Novakofski et al., 1989). Crude protein content (nitrogen x 6.25) was determined by the 
combustion method (AOAC, 2000; method 990.03) with a Leco model FP2000 (Leco 
Corp., St. Joseph, MI), using EDTA as an internal standard. Total body fat and protein 
were calculated by summing the fat or protein from each sub-sample and dividing by 
total body weight. 
Serum Analysis 
 A subset of animals (n=4-6 for each genotype by diet combination) were selected 
from the first replicate for serum analysis. Serum insulin was determined in duplicate by 
ELISA (Linco Research Inc, St. Charles, MO) according to manufacturer directions. 
Serum triglycerides were determined by the enzymatic measurement of glycerol after 
lipase digestion of serum triglycerides following the procedures of a Serum Triglyceride 
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Determination Kit (Sigma-Aldrich Company, St. Louis, MO). Free glycerol was also 
measured and used to correct for true triglyceride content. Gene expression 
 A subset of animals (n=4-8 from each genotype by diet combination) were 
selected from the first replicate for gene expression analysis of liver, biceps femoris(fast, 
glycolytic muscle), gastrocnemius muscle (more intermediate in fiber type) and 
epididymal fat.  
 Total RNA was prepared by disrupting tissues in TRIzol reagent (Invitrogen, 
Carlsbad, CA) with a TissueLyzer (Qiagen, Valencia, CA) following manufacturer’s 
instructions. Concentration and RNA purity was determined spectrophotometrically and 
samples with 260:280 ratios of less than 1.8 were repurified (RNeasy Mini kit; QIAGEN, 
Valencia, CA). One microgram of RNA was treated with DNAase before reverse 
transcription into cDNA (Quantitect Reverse Transcription kit, Qiagen, Valencia, CA). 
Expression of specific mRNAs was quantitated by Taqman real-time reverse 
transcriptase-polymerase chain reaction (RT-PCR) normalized to GAPDH. The Taqman 
primer/probe sets for all genes examined were obtained from Applied Biosystems (Foster 
City, CA). Data are presented as mean fold change compared with wild type mice fed 
normal diets (control).   
Statistical Analysis 
Statistical analyses were performed using SAS version 9.1 (SAS Institute Inc, 
Cary, NC). Analysis of variance was used to determine the significance of genotype 
(Mstn null or wild type), diet (normal or high fat) and their interaction employing the 
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Mixed procedure of SAS. Replicate was used as a random variable in the analysis of 
body and tissue weights and glucose measurements from 16 weeks of age while plate was 
used a random variable for gene expression analysis. For body weight and food intake, 
analysis included repeated measures with an autogressive variance/covariance structure. 
Week of age was included in the model for the analysis of glucose data from replicate 2 
which included glucose tolerance tests at 8, 12 and 16 weeks of age. Data are presented 
as lsmeans ± S.E.M with P-values for the main effects of genotype, diet and their 
interaction where appropriate.  
Results and Discussion 
Weight, Body Composition, and Efficiency 
Body weight of Mstn null and wild type mice did not differ at the beginning of the 
trial (4 weeks of age). Body weight increased for the remainder of the trial and was 
impacted by genotype, diet and their interaction (Figure 3.1). Mstn null mice gained more 
weight than wild type mice (P < 0.05). Furthermore, mice fed high-fat diets were heavier 
than mice fed control diets. The interaction of genotype and diet was also significant 
from weeks 6-12 of dietary treatment. While consumption of fed high-fat diets increased 
body weight of Mstn null mice, this diet effect was lower than similarly fed wild type 
mice. After 12 weeks of feeding, high-fat fed Mstn null mice were 11% heavier than 
control-fed Mstn null mice while high-fat fed wild type mice were 39% heavier than 
control-fed wild type mice.  
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From the second replicate, mice were used to estimate body fat and protein 
content and liver fat content (Table 3.1). Prior to diet initiation, Mstn null mice had less 
body fat than wild type but protein was not different. After 12 weeks of dietary treatment, 
on diets, body protein was increased (P < 0.05) and body fat was decreased (P < 0.05) in 
Mstn null mice compared with wild type mice. Furthermore, high-fat fed mice had more 
body fat than control mice (P < 0.05). However, there was a significant interaction of 
genotype and diet for body fat (P = 0.04). Body fat more than doubled (109% increase) in 
high-fat fed wild type mice compared with control wild type mice. In Mstn null mice, 
however, body fat increased 44% in high-fat fed animals compared with control. The 
interaction of genotype and diet was also significant for body protein content (P = 0.02).  
In high-fat fed wild type mice body protein was reduced compared with control wild type 
mice, while in Mstn null mice, it was unchanged by high-fat feeding. 
Body composition was used to estimate body energy content using the 
conversions of 4.27 kcal/g protein and 8.79 kcal/g fat. Body energy content was not 
different between the two genotypes either prior to start of the study or after 12 weeks of 
dietary treatment. High-fat feeding, however, did increase body energy compared with 
the control diet, and similar to body fat content, the increase in body energy content with 
high-fat feeding was less pronounced in Mstn null mice compared with wild type. Body 
energy increased 40% in high-fed fed Mstn null mice while it increased 130% in 
similarly fed wild type mice compared with respective genotype controls.  
Food intake was also impacted by genotype, diet and their interaction, but did not 
differ with time. Food intake was increased (P < 0.05) in Mstn null mice fed control diets 
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compared with similarly fed wild type mice. However, food intake was reduced (P < 
0.05) in mice fed high-fat diets compared with control diets (Table 3.2) of both 
genotypes. The reduction in food intake in high-fat fed Mstn null mice was greater than 
in wild type mice (28% compared with 16%). Efficiency of gain (mg gain/ g food 
consumed) was not impacted by genotype but was higher in high-fat fed mice than 
control mice. The interaction of genotype and diet was also significant as efficiency of 
gain doubled in high-fat fed wild type mice but was only increased 44% in Mstn null 
mice compared with control-fed mice of each genotype, respectively.  
Though food intake was reduced in high-fat fed mice, the high-fat diet was more 
calorically dense than the control diet, therefore, caloric intake of high-fat fed mice was 
greater (P < 0.05) in mice receiving high-fat diet compared with control diet. Calorie 
consumption in wild type mice increased 17% with high-fat feeding compared with the 
control diet. Increased calorie consumption was not as pronounced in Mstn null mice 
(increased less than 10%). Caloric gain was estimated from body energy calculations 
(Table 3.1) and used to calculate caloric efficiency. Similar to efficiency of gain, caloric 
efficiency was increased in high-fat fed mice. However, unlike efficiency of gain, Mstn 
null mice were less efficient at depositing food calories into body energy than wild type 
mice. Furthermore, there was an interaction of genotype and diet as the increased caloric 
efficiency of high-fat fed mice was less pronounced in Mstn null compared with wild 
type mice.  
 Similar to body fat content, fat pads from Mstn null mice weighed less (P < 0.01)  
than those of wild type mice and high-fat fed mice had heavier fat pads (P < 0.01)  than 
58 
 
control mice (Table 3.3). Additionally, there was a significant interaction of genotype and 
diet as high-fat feeding caused a greater increase in fat pad weights of wild type mice 
compared with Mstn null mice. However, the interaction of diet and genotype was not 
significant for muscle weights, and the effect of diet was only significant for the biceps 
femoris muscle (Table 3.3). High-fat fed mice had heavier (P < 0.05) gastrocnemius 
muscle than control mice. Overall, muscles of Mstn null mice were heavier (P < 0.05) 
than muscles of wild type mice.  
 These data are similar to previous studies (Guo et al., 2009; Hamrick et al., 2006; 
McPherron and Lee, 2002) though mice in our study were subjected to a higher fat diet 
(60% kcal from fat compared with 45%) for a longer period of time (12 weeks compared 
with 8-10 weeks). Furthermore, our study is the first to provide critical information on 
body composition analyses of Mstn null mice fed control and high-fat diets. It should be 
noted, however, that Mstn null mice are not completely resistant to fat accumulation 
under conditions of excess caloric intake. Other mice with modified Mstn function, those 
with transgenic overexpression of Mstn pro-peptide, exhibited increased muscularity, but 
after 9 weeks of feeding a diet with 45% kcal from fat, no increase in fat pad weight was 
observed (Yang and Zhao, 2006; Zhao et al., 2005). This discrepancy may result from 
older mice being used in the transgenic overexpression study, 9 weeks old compared with 
4 weeks old in this study. It is also possible that the pro-peptide of Mstn has a role 
separate from the inhibition of Mstn directly, and thus further inhibits fat accumulation in 
the presence of excess calories. These data confirm that the Mstn null mutation only 
partially blunts the development of high-fat diet induced obesity as body weight gain and 
body fat accumulation were less pronounced in Mstn null mice compared with similarly 
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fed wild type mice. Furthermore, efficiency of weight and caloric gain were increased to 
a lesser degree in Mstn null mice compared with high-fat fed wild type mice. 
Glucose Tolerance and Markers of Metabolic Syndrome 
Frequently, diet-induced obesity is accompanied by insulin resistance, and 
mutations or compounds which confer resistance to diet-induced obesity often also 
improve insulin resistance. Furthermore, reduced fasting blood glucose has been noted in 
Mstn null mice previously (Guo et al., 2009). However, in our study, fasting blood 
glucose was not different between wild type and Mstn null mice at any time point of 
dietary treatment (Figure 3.2 A) There was also no interaction of genotype and diet for 
fasting glucose at any time point. However, fasting blood glucose was greater (P < 0.05) 
in high-fat fed mice than in control mice after 4 weeks on high-fat diet and this increase 
persisted through the end of the study though as time on high-fat diet increased, fasting 
blood glucose decreased. Blood glucose was higher (P < 0.05) in high-fat fed mice than 
in control mice at all time points post-glucose challenge resulting in a greater area under 
the curve in high-fat fed compared with control-fed mice (12 week data, Figure 3.2 B). 
Glucose tolerance tests at 4 and 8 weeks on diet followed a similar pattern with that of 12 
weeks on diet described above (data not shown). This resulted in increased area under the 
curve for high-fat fed mice with no effect of genotype or interaction at any time point 
(Figure 3.2 C). As time on high-fat diet increased, however, area under the curve also 
increased indicative of progressing insulin resistance. Given the results of previous 
studies (Guo et al., 2009; McPherron and Lee, 2002; Zhao et al., 2005), the lack of 
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improvement in glucose metabolism in high-fat fed Mstn null mice compared with 
similarly fed wild-type mice was surprising.  
Serum triglyceride content, serum insulin levels and liver fat content are all 
correlated with metabolic syndrome of which insulin resistance is a common feature 
(Marchesini et al., 2003; Taskinen, 2003). Given the insulin resistance present in high-fat 
fed mice of both genotypes, increased insulin, triglycerides and liver fat were expected 
outcomes. However, in our study, insulin and triglycerides were increased in serum of 
high-fat fed wild type mice but not in high-fat fed Mstn null mice (Figure 3.3 A,B). 
Furthermore, liver fat content was increased with high-fat feeding in wild type mice, but 
decreased in high-fat fed Mstn null mice (Table 3.1). Finally, several adipokines are 
related to obesity and insulin resistance. Leptin levels are reflective of lipid content in 
mice, and increased leptin is associated with obesity (Frederich et al., 1995). Leptin 
expression in adipose tissue was increased with high-fat feeding in this study, but was 
unaffected by genotype (Figure 3.4).  Conversely, adiponectin is decreased in obese or 
insulin resistant individuals (Yamauchi et al., 2001). In this study, adiponectin expression 
in epididymal fat of high-fat fed wild type mice is unaltered, but it is increased in Mstn 
null mice fed high-fat diets (Figure 3.4). This would suggest improve insulin sensitivity 
which is not reflected in the glucose data.  
Mechanism of Obesity Resistance 
There are several possible mechanisms for the resistance to fat accumulation 
observed in Mstn null mice. Increased lipid mobilization and thermogenesis was the 
focus of the gene expression analysis in our study. By uncoupling oxidative 
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phosphorylation from ATP production, uncoupling proteins (UCP) allow energy to be 
dissipated as heat (Ricquier and Bouillaud, 2000). Increased UCP expression in adipose 
(Kopecky et al., 1995) or muscle (Li et al., 2000) tissue has been shown to counteract 
diet-induced obesity and therefore, it is tempting to speculate that the reduced fat gain in 
Mstn null mice may result from increased UCP expression. Previous reports have noted 
no changes in UCP expression in fat or muscle tissue of Mstn null mice compared with 
wild type mice (McPherron and Lee, 2002). Similarly, in this study, UCP 3 expression 
was not different between Mstn null and wild type mice in muscle tissue (Table 3.4). 
Recently, it was suggested that UCP 1 expression in intermuscular brown adipocytes 
explained differences in obesity-susceptibly between two strains of mice (Almind et al., 
2007). In this study, the muscle form of UCP, UCP 3, was quantified, thus it is unknown 
if ectopic expression of UCP 1 in Mstn null mice may explain their resistance to fat 
accumulation.  
Two other candidate genes to explain the reduced fat accumulation in Mstn null 
mice are PGC 1α and PGC 1β. These co-activators are involved in regulating 
mitochondrial oxidative metabolism. Expressed in several tissues with a high oxidative 
capacity, the specific roles of PGC 1β are less well-understood than PGC 1α, though their 
functions overlap in many tissues. In other obesity-resistant mouse models, PGC 1 
expression is increased (Lau et al., 2008; Toh et al., 2008) corresponding to increased 
mitochondrial activity in adipose tissue. Increased expression of PGC 1β results in 
obesity resistance (Kamei et al., 2003) while expression of PGC 1α is depressed in 
morbidly obese subjects. Furthermore, subjecting chicks to cold conditions reduced Mstn 
expression while increasing PGC 1α expression in sartorius muscle (Ijiri et al., 2009). 
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Therefore, an increased expression of PGC 1 was expected in Mstn null mice. 
Conversely, reduced expression of PGC 1β in biceps femoris and gastrocnemius muscles 
and reduced expression of PGC 1α in gastrocnemius muscles of Mstn null mice was 
observed (Table 3.4). This phenomenon, however, may be more related to muscle fiber 
type in Mstn null mice than to proposed alterations in oxidative metabolism. Though not 
directly observed in our study, Mstn null mice are thought to possess more fast-twitch 
muscle fibers than wild type mice (Girgenrath et al., 2005). This can be inferred in our 
data due to the decrease in MHC I expression in both biceps femoris and gastrocnemius 
muscles (Table 3.4). On the other hand, PGC 1α expression drives the formation of slow 
twitch fibers as evidenced by mice with transgenic PGC 1α expression (Lin et al., 
2002b). Similar transgenic expression of PGC 1β drives the formation of oxidative fibers 
expressing MHC IIx (Arany et al., 2007). Thus, the reduction in MHC I, IIa and IIx 
expression in gastrocnemius and biceps femoris muscles may explain the concomitant 
reduction in PGC 1 expression.   
In epididymal fat, however, PGC 1β expression was specifically upregulated in 
high-fat fed Mstn null mice compared with all other treatments. Similarly, adipose 
triglyceride lipase expression was increased in high-fat fed Mstn null mice compared 
with all other treatments. With a role similar to that of hormone-sensitive lipase, adipose 
triglyceride lipase is responsible for the hydrolysis of tri- and diacylglycerols with a 
preference for the hydrolysis of primary ester bond (Zimmermann et al., 2004). Thus, an 
increased expression of adipose triglyceride lipase would suggest increased lipolysis 
within the adipocyte. In epididymal fat, UCP 2 expression was increased by high-fat 
feeding but it did not differ between the two genotypes (Figure 3.4). This coupled with 
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increased PGC 1β and adipose triglyceride lipase expression in the same tissue may 
indicate an increase in thermogenesis. However, the main source of thermogenesis in 
rodents is brown adipose tissue. This type of adipose differs from the epididymal fat pad 
used in this experiment in that it has a larger capacity for thermogenesis. Therefore, 
determining the expression of UCP and other genes involved in thermogenesis in 
subscapular (brown) fat of Mstn null mice is warranted. 
Furthermore, it is also possible that the apparent “energy-wasting” phenomenon 
observed in Mstn null mice (i.e. reflected by reduced fat accumulation while consuming 
excess calories) may be unrelated to thermogenesis. Protein turnover, which is required to 
maintain normal muscle function for example, is a large part of resting energy 
expenditure (Welle and Nair, 1990). Muscle weight of Mstn null mice is increased 75-
100% compared with wild type mice; this would imply a greater amount of protein 
turnover is needed in Mstn null mice. In fact, Mstn null mice have been shown to have a 
higher metabolic rate (McPherron and Lee, 2002). However, this increase is attenuated if  
corrected for lean mass, which suggests the increased lean mass is responsible for the 
increased metabolic rate. There is also evidence that protein turnover, like adaptive 
thermogenesis, may be an adaptation to maintain body weight when presented with an 
excess of calories. Protein turnover was shown to be increased in obese individuals 
(Welle and Nair, 1990) and recently, mice lacking a gene responsible for branched-chain 
amino acid metabolism exhibited diet-induced obesity resistance with increased protein 
turnover in the absence of thermogenic alterations. Thus, increased protein turnover in 
Mstn null mice, occurring as a result of increased muscle mass or as a specific adaptation 
to the high-fat diet, may explain their partial resistance to obesity development. Though 
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Mstn expression has been implicated in muscle atrophy (Ma et al., 2003), rates of protein 
turnover have not been established in Mstn null mice.  
In conclusion, the Mstn null mutation resulted in a partial blunting of the effects 
of high-fat feeding. Though Mstn null mice fed high-fat diets did exhibit an increase in 
body fat content, this increase was less pronounced than in wild type mice. Furthermore, 
other markers of the metabolic syndrome often associated with high-fat diet-induced 
obesity, namely serum triglyceride and liver fat content, were also improved in Mstn null 
mice compared with wild type mice. Unlike other mutations or conditions which result in 
obesity resistance, however, the Mstn null mutation did not protect against the 
development of insulin resistance as evidence by increased blood glucose levels 
following glucose injection of mice fed high-fat diets compared with control-fed mice. 
Though some genes involved in adaptive thermogenesis were specifically upregulated in 
high-fat fed Mstn null mice, the mechanism by which Mstn null mice resist obesity is still 
unclear. A closer investigation of metabolic rate, specifically related to protein turnover 
given the increased lean mass in Mstn null mice, is warranted.    
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Figure 3.1. Body weight of Mstn null (light circles) and wild type (dark diamonds) mice 
fed control (solid lines) and high fat (dashed lines) diets for 12 weeks (4-16 weeks of 
age). Effect of time, genotype, diet, and interactions were significant (P< 0.05) and are 
shown.  
 
Source P-value 
Time < 0.01 
Genotype < 0.01 
Diet < 0.01 
Genotype x Diet 0.03 
Genotype x Diet x Time < 0.01 
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 Figure 3.2. Fasting blood glucose (A) and total area under the curve for glucose values 
during glucose tolerance tests (C) of Mstn null and wild type mice prior to dietary 
treatment and at 4, 8, and 12 weeks on high fat and control diets. * indicates different 
than wild type control (P < 0.05). Data presented as least square means ± standard error.  
(B) Blood glucose values during glucose tolerance tests of myostatin (Mstn) null (light 
circles) and wild type (dark diamonds) mice after control (solid lines) or high fat (dashed 
lines) diets were fed for 12 weeks. Effect of diet on glucose values was significant (P < 
0.01) while genotype effect and interaction were not significant (N.S.).  
 
 
Source P-value 
Diet < 0.01 
Week  0.05 
Week x Diet < 0.01 
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Figure 3.2 (cont.) 
Source P-value 
Genotype N.S. 
Diet < 0.01 
Genotype x Diet N.S. 
Source P-value 
Diet < 0.01 
Week  0.05 
Week x Diet < 0.01 
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Figure 3.3. Serum triglycerides (A) and insulin (B) of wild type and Mstn null mice after 
control and high fat diets were fed for 12 weeks. Bars are least square means ± standard 
error. Bars with different letters differ (P < 0.05). 
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Figure 3.4. Weight and gene expression of epididymal fat in wild type and myostatin 
(Mstn) null mice after receiving control and high fat diets for 12 weeks. Mean fold 
change compared with wild type mice fed control diets ± standard error are displayed. 
Bars with different letters are different (P < 0.05). Abbreviations: PPARγ coactivator 1β 
(PGC 1β); uncoupling protein 3 (UCP 2) 
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Table 3.1. Effects of genotype (G) and diet (D) and their interaction (GxD) on body and liver composition of wild type and myostatin 
null mice prior to (baseline) and after consuming control or high fat diets for 12 weeks1 
 Wild Type  Myostatin Null   P-value 
  Control High Fat  Control High Fat SEM  G  D GxD
Baseline 
   Number of mice 5 -- 5 -- -- -- 
   Body fat (%)2 6.1 -- 4.8 -- 0.31 0.02 -- -- 
   Body protein (%)2 17.2 -- 17.3 -- 0.57 0.88 -- -- 
   Body energy (kcal)3 20.2 -- 18.8 -- 1.53 0.56 -- -- 
   Liver fat (%)2 7.2 -- 7.7 -- 0.67 0.64 -- -- 
12 weeks 
   Number of mice 5 5 5 5 
   Body fat (%)2 12.4 25.9 8.5 12.2 2.22 <0.01 <0.01 0.04 
   Body protein (%)2 18.3 15.2 19.5 19.3 0.59 <0.01 0.01 0.02 
   Body energy (kcal)3 45.6 103.5 48.2 67.1 9.94 0.11 <0.01 0.07 
   Liver fat (%)2 9.8 13.4 8.1 5.4 1.91 0.02 0.83 0.11 
1 Mice were provided ad libitum access to control (10% kcal from fat) or high fat (60% kcal from 
fat) diets. Values are lsmeans ± S.E.M.  
2 Body fat and protein are expressed as a percentage of body weight. Liver fat is expressed as a 
percentage of liver weight. 
3 Body energy was calculated from body fat and protein content assuming 8.79 kcal/g of fat and 
4.27 kcal/g of protein. 
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Table 3.2. Effects of genotype (G) and diet (D) and their interaction (GxD) on food intake, caloric intake and efficiency of weight gain 
in wild type and myostatin null mice fed control or high fat diets for 12 weeks1 
 
 
  Wild Type  Myostatin Null  P-value 
  Control High Fat  Control High Fat  G  D GxD 
Number of mice 11 11 12 9 
Weight gain (g) 12.2 ± 1.00 22.9 ± 1.00 17.4 ± 0.96 20.2 ± 1.10 0.23 <0.01 <0.01
Food intake (g) 245.2 ± 3.72 211.2 ± 3.72 265.2 ± 3.56 213.8 ± 4.11 <0.01 <0.01 0.03
Efficiency of gain (mg/g) 2 50.1 ± 3.94 107.7 ± 3.94 65.7 ± 3.77 94.5 ± 4.35 0.76 <0.01 <0.01
Caloric intake (Kcal) 3 944 ± 17.1 1107 ± 17.1 1021± 16.3 1120 ± 18.9 0.01 <0.01 0.08
Caloric Efficiency (%) 4 2.7 ± 0.24 7.5 ± 0.24 2.9 ± 0.23 4.3 ± 0.26 <0.01 <0.01 <0.01
1 Mice were provided ad libitum access to control (10% kcal from fat) or high fat (60% kcal from fat) diets. 
Values are lsmeans ± S.E.M. 
2 Efficiency of gain was calculated by dividing weight gain (mg) by food intake (g).  
3 Calculated from dietary caloric density: control, 3.85 kcal/g; high fat: 5.24 kcal/g. 
4 Caloric efficiency was calculated by dividing caloric gain, estimated from body composition data, by caloric 
intake x100. 
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Table 3.3. Effects of genotype (G) and diet (D) and their interaction (GxD) on fat pad and muscle weights of wild type and myostatin 
null mice fed control or high fat diets for 12 weeks1 
 
 Wild Type  Myostatin Null  P-value 
  Control High Fat  Control High Fat  G  D GxD 
Number of mice 17 16 17 14 
Fat pad weight (mg) 
   Epididymal     724 ± 115.2 2055 ± 115.2 249 ± 111.8  768 ± 123.2 <0.01 <0.01 <0.01
   Inguinal    450 ± 115.6 1711 ± 115.6 192 ± 112.1 444 ± 123.5 <0.01 <0.01 <0.01
   Retroperitoneal  186 ± 36.2 572 ± 26.2 35 ± 35.1  200 ± 38.7 <0.01 <0.01 <0.01
   Subscapular  339 ± 78.6 1038 ± 78.6 87 ± 76.2  340 ± 84.0 <0.01 <0.01 <0.01
Muscle weight (mg) 
   Tibalis Anterior      69 ± 3.0 72 ± 3.0 119 ± 2.9  125 ± 3.2 <0.01 0.14 0.52
   Triceps Brachii       90 ± 6.4 97 ± 6.4 182 ± 6.2  194 ± 6.8 <0.01 0.16 0.69
   Biceps Femoris     129 ± 6.5   133 ± 6.5 223 ± 6.3  234 ± 7.0 <0.01 0.04 0.66
   Gastrocnemius     139 ± 4.9   150 ± 4.9 265 ± 4.8  274 ± 5.3 <0.01 0.25 0.66
1 Mice were provided ad libitum access to control (10% kcal from fat) or high fat (60% kcal from fat) diets. 
Values are lsmeans ± S.E.M. 
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Table 3.4. Effects of genotype (G) on expression fold changes of genes in bicep femoris and gastrocnemius muscles of wild type and 
myostatin (Mstn) null mice fed control diets for 12 weeks 1 
 
  Biceps Femoris  Gastrocnemius 
Wild Type Mstn Null SEM P-value  Wild Type Mstn Null SEM P-value 
Number of mice 8 8   8 8   
 MHC I 1.51 0.50 0.372 0.08  1.06 0.80 0.124 0.16 
 MHC IIa 1.06 0.13 0.087 <0.01  1.04 0.20 0.083 <0.01 
 MHC IIx 1.18 0.32 0.177 <0.01  1.10 0.06 0.129 <0.01 
 MHC IIb 1.02 1.20 0.088 0.17  1.03 1.14 0.091 0.40 
 PGC 1α 1.22 0.87 0.206 0.25  1.06 0.59 0.095 <0.01 
 PGC 1β 1.25 0.52 0.219 0.03  1.12 0.19 0.131 <0.01 
 UCP 3 1.03 1.05 0.180 0.96  1.02 1.33 0.132 0.12 
 LPL 1.19 0.58 0.211 0.07  1.09 1.77 0.292 0.13 
1 Values are least square means compared with a calibrator group. Abbreviations: myosin heavy chain (MHC), 
peroxisome-proliferator activated receptor γ coactivator (PGC), uncoupling protein (UCP), lipoprotein lipase (LPL). 
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GENERAL SUMMARY 
 
Though the phenotype of myostatin (Mstn) mutant animals is very striking, the question 
remains whether the loss of Mstn function fundamentally changes growth potential, metabolism, 
or inherent regulation in tissues, or if it simply is an effect independent of other factors. To that 
end, we sought to increase muscle growth even further in Mstn null mice through the use of the 
β-adrenergic agonist (βAA) clenbuterol. We also aimed to alter the fat accumulation and 
metabolism of Mstn null mice by feeding diets high in fat.   
 
Clenbuterol Treatment of Myostatin Null Mice 
Overall, the individual effects of clenbuterol and ablation of Mstn function share some 
phenotypic similarities including increased protein accretion and reduced fat accumulation. 
Clenbuterol treatment increases expression of faster muscle fiber types (Oishi et al., 2004), and 
Mstn null mice inherently possess more fast fibers, as well. Additionally, both treatments also 
involve the Akt/mTOR pathway, thereby stimulating translation of new proteins (Amirouche et 
al., 2009; Kline et al., 2007). There are, however, some differences in the two proposed 
mechanisms. Loss of Mstn function results in prenatal muscle hyperplasia (Thomas et al., 2000) 
and increased satellite cell activity (McCroskery et al., 2003). Clenbuterol treatment may alter 
satellite cell activation (Maltin and Delday, 1992), but cannot result in muscle cell hyperplasia as 
muscle cell number is largely set at birth. Thus, we hypothesized that the mechanisms of each 
effect were different enough so as to be additive. 
The results of our study reveal that the effects of clenbuterol treatment and the lack of 
Mstn function were completely additive for body weight, carcass composition, and muscle and 
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fat pad weights. The interaction of clenbuterol treatment and genotype—indicative of a less than 
additive respsonse—was only significant for gastrocnemius muscle weight. In this case, the 
magnitude of the difference, less than 2 mg, was very small. For all other traits, the two effects 
were completely additive. These data suggest that the mechanism of increased muscle growth 
from βAA treatment and ablation of Mstn function are indeed independent.  
Additionally, these data suggest that regulation of Akt/mTOR signaling may comprise 
only a small part of either the effect of clenbuterol or of Mstn deletion. Myostatin inhibits mTOR 
signaling while clenbuterol activates it. Thus, the loss of myostatin and the administration of 
clenbuterol may result in the same effect—increased mTOR signaling. The additive effects of 
Mstn deletion and clenbuterol indicate that mTOR is not the only pathway responsible for 
increased muscle protein accretion in this model or that each single treatment does not maximize 
mTOR signaling. It would therefore be interesting in future work to investigate mTOR signaling 
in Mstn null mice to determine if the loss of Mstn function in these mice does alter its’ 
regulation. 
 With regard to fat accumulation, reductions due the loss of Mstn function and from 
clenbuterol treatment were fully realized in our experiment. Body fat composition and fat pad 
weights were reduced by clenbuterol treatment in both wild type and Mstn null mice. 
Clenbuterol directly impacts lipolysis and lipogenesis through activation and inhibition of 
enzymes. The impact of the Mstn null mutation on fat accumulation, however, may be more 
indirect.  
Overall, the results of clenbuterol treatment in Mstn null mice suggest that β-adrenergic 
signaling is not altered by the loss of Mstn function. A microarray analysis of this model was 
performed and will be detailed in full in another work. Results from this analysis, however, 
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confirm that clenbuterol treatment in Mstn null and wild type mice is additive with regards to 
gene expression changes. Improvements to our study include a histological analysis of muscle 
cells to confirm muscle hypertrophy in both wild type and Mstn null mice treated with 
clenbuterol. Furthermore, measuring down-stream signals of β-adrenergic signaling in muscle 
cells and adipocytes would confirm that β-adrenergic signaling is not altered in Mstn null mice.   
 
High-fat Diet-induced Obesity in Myostatin Null Mice 
Given the larger muscle mass of Mstn null mice, we hypothesized that insulin-stimulated 
glucose uptake may be increased simply due to a greater amount of tissue available for activity. 
However, slow, oxidative fibers are more insulin responsive than fast, glycolytic fibers (Kriketos 
et al., 1996) and an increased amount of slow, oxidative fibers has been shown to be associated 
with resistance to obesity in rats (Abou Mrad et al., 1992). Thus, given the increased fast, 
glycolytic phenotype of Mstn null mice, it is possible that they are less, and not more, resistant to 
obesity.  
As previously detailed, there is some evidence to suggest that Mstn null mice are partially 
resistant to the effects of high-fat diets (Guo et al., 2009; Hamrick et al., 2006). However, one 
criticism of these studies is that they did not employ mouse strains with increased propensity for 
obesity caused by high-fat diets. Thus, strain-specific differences may serve as a confounding 
factor in this line of research.  
Our study confirms, in an obesity-prone strain, that Mstn null mice are partially resistant 
to high-fat diet-induced obesity. Fat accumulation was increased in high-fat fed Mstn null mice 
compared with control-fed Mstn null mice. The increase in fat accumulation in high-fat fed Mstn 
null mice, however, was much less than that of high-fat fed wild type mice. Overall, high-fat 
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feeding of Mstn null mice resulted in body fat accumulation similar to control-fed wild type 
mice. As caloric and fat intake was increased in all high-fat fed mice, the lack of obesity in Mstn 
null mice would suggest adaptive energy wasting in this genotype. Expression of genes involved 
in white adipose tissue thermogenesis including PGC 1β and UCP 2 were increased in high-fat 
fed Mstn null mice compared with wild type mice. Lipid mobilization and thermogenic genes in 
skeletal muscle of Mstn null mice, however, were not altered in a way that would suggest 
improved thermogenesis in these animals. Though characterization of brown adipose tissue 
thermogenesis is needed in this model, it does not appear that altered thermogenesis explains the 
reduced fat accumulation in Mstn null mice. It is plausible that increased protein turnover due to 
the increase in muscle mass in Mstn null mice may be a source of “energy wastage” and account 
for the decreased fat accumulation in both control and high-fat fed Mstn null mice. 
Characterization of rates of protein turnover with and without the addition of high-fat diets in 
Mstn null mice may elucidate the mechanism of decreased fat accumulation in these mice.  
In conclusion, altering muscle and fat mass in Mstn null mice is certainly possible. While 
the phenotype of Mstn null mice is extreme, this mutation alone does not result in maximal 
muscle growth or minimal fat accumulation. Muscle growth can be increased and fat growth 
decreased by clenbuterol treatment. High-fat feeding increases adipose growth in Mstn null 
animals.  
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APPENDIX 
Glucose Tolerance Tests 
Figure A.1 Blood glucose values during glucose tolerance tests of myostatin (Mstn) null 
(light circles) and wild type (dark diamonds) mice at 4 weeks of age and prior to dietary 
treatments. Genotype effect was not significant. 
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Figure A.2 Blood glucose values during glucose tolerance tests of myostatin (Mstn) null 
(light circles) and wild type (dark diamonds) mice after control (solid lines) or high fat 
(dashed lines) diets were fed for 4 weeks. Effect of diet on glucose values was significant 
(P < 0.01) while genotype effect and interaction were not significant (N.S.).  
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Figure A.3 Blood glucose values during glucose tolerance tests of myostatin (Mstn) null 
(light circles) and wild type (dark diamonds) mice after control (solid lines) or high fat 
(dashed lines) diets were fed for 8 weeks. Effect of diet on glucose values was significant 
(P < 0.01) while genotype effect and interaction were not significant (N.S.).  
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Diet Formulations 
Diets from Chapter 3 obtained from Research Diets Incorporated, New Brunswick, NJ.  
Control Diet High Fat Diet 
Product # D12450B Product # D12492 
% of diet % of kcal % of diet % of kcal 
Protein 19.2 20 26.2 20 
Carbohydrate 67.3 70 26.3 20 
Fat 4.3 10 34.9 60 
g/kg % of kcal g/kg % of kcal 
Casein, 80 Mesh 189.6 19.72 258.4 19.72 
L-Cystine 2.8 0.30 3.9 0.30 
Corn Starch 298.6 31.06 0 0 
Maltodextrin 10 33.2 3.45 161.5 12.32 
Sucrose 331.7 34.51 88.9 6.78 
Cellulose, BW200 47.4 0 64.6 0 
Soybean Oil 23.7 5.55 32.3 5.55 
Lard 19.0 4.44 316.6 54.35 
Mineral Mix, S10026 9.5 0 12.9 0 
Dicalcium Phosphate 12.3 0 16.8 0 
Calcium Carbonate 5.2 0 7.1 0 
Potassium Citrate 15.6 0 21.3 0 
Vitamin Mix, V1001 9.5 0.99 12.9 0.99 
Choline Bitartrate 1.9 0 2.6 0 
FD&C Blue Dye #1 0 0 0.06 0 
FD&C Yellow Dye #5 0.05 0 0 0 
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Calculations for Area under the Curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
Area under the curve for glucose tolerance was calculated using a trapezoidal method. 
The data above are for demonstration purposes and correspond to glucose readings of 100 
at 0 minutes, 300 at 30 minutes, 275 at 60 minutes, 200 at 90 minutes and 150 at 120 
minutes post injection. Minutes are on the horizontal axis and glucose on the vertical 
axis.  
First, the area of each outlined trapezoid is calculated and summed together.  
Trapezoid A: (100+300)/2 x 30 = 6000 
Trapezoid B: (300+275)/2 x 30 = 8625 
Trapezoid C: (275+200)/2 x 30 = 7125 
Trapezoid D: (200+150)/2 x 30 = 5250 
6000 + 8625+7125+5250 = 27000 
Then, the area below the baseline reading (shaded area) is calculated as follows and subtracted 
from the trapezoidal sums: 
A B C D 
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Baseline area: 100x120=12000 Area under the curve: 27000-12000=15000 
Protocol for RNA Extraction, cDNA Synthesis and Gene Expression 
RNA Extraction 
1. Prepare tissue for extraction by placing 50-100 mg into an Eppendorf Safe-lock tube. 
2. Add 1 ml Trizol solution and keep on ice.  
3. Disrupt in the Tissuelyzer for 3 minutes on 30 Hz.  
4. Centrifuge at 4ºC for 15 minutes at 14,000xg.  
5. Remove supernatant and add to new 1.5 ml tubes containing 100 µl BCP (1-bromo-3-
chloropropane).  
6. Mix by vortexing 15 s. Incubate at room temperature for at least 10 minutes. 
7. Centrifuge at 4ºC for 15 minutes at 12,000xg.  
8. Transfer upper phase into new 1.5 ml tubes containing 500µl isopropanol. Place in -20ºC 
freezer overnight. 
9. Centrifuge at 4ºC for 15 minutes at 12,000xg and RNA pellet will form. 
10. Decant supernatant and add 1 ml 75% ethanol. Vortex sample to disturb but not dissolve 
pellet. 
11. Centrifuge at 4ºC for 15 minutes at 12,000xg.  
12. Decant supernatant and allow pellet to air dry. 
13. Add 25 µl DNAase-free water and quantify RNA concentration and purity with 
Nanodrop. 
14. Dilute RNA with DNAase-free water to concentration of 500 ng/ml. 
 
cDNA Synthesis—Qiagen Quantitect Reverse Transcription Kit 
1. Mix DNA-wipeout solution by adding 2 µl DNA Wipeout and 10µl water to 2µl of each 
RNA sample. 
2. Incubate according to kit directions. 
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3. Mix Transcriptase solution by adding 1 µl transcriptase, 4 µl buffer and 1 µl primers to 
each sample. 
4. Incubate according to kit directions. 
5. Use cDNA immediately or store at -20ºC. 
 
Gene Expression—Taqman Primer/Probe Kits 
1. Dilute cDNA as appropriate based on validation tests. For muscle samples, a 1:100 
dilution usually works well. 
2. Add 2µl of Primer/Probe to 20 µl Taqman Universal PCR Master Mix for each reaction. 
3. Add 18µl cDNA to master mix. 
4. Pipette 10µl in triplicate into 384 well plate.  
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